Tempus to buy cancer test-maker Personalis for $1.5B

Tempus to buy cancer test-maker Personalis for $1.5B is a pharma and life sciences industry update from MedTech Dive. The story may affect commercial strategy, market access planning, stakeholder engagement, competitive positioning, and near-term monitoring for pharmaceutical and biotech teams.

Elise Reuter · 2026-07-20

Tempus AI’s planned acquisition follows recent interest in blood-based cancer tests across the medtech industry.

Source: MedTech Dive